Natural diosmin alleviating obesity and nonalcoholic fatty liver disease by regulating the activating the AMP-activated protein kinase (AMPK) pathway.
10.1016/S1875-5364(25)60914-9
- Author:
Can LIU
1
;
Siyu HAO
1
;
Mengdi ZHANG
1
;
Xueyu WANG
1
;
Baiwang CHU
1
;
Tingjie WEN
1
;
Ruoyu DANG
2
;
Hua SUN
3
Author Information
1. College of Biotechnology, Tianjin University of Science & Technology, Tianjin 300457, China.
2. College of Pharmacy, Nankai University, Tianjin 300353, China.
3. College of Biotechnology, Tianjin University of Science & Technology, Tianjin 300457, China. Electronic address: sunhua@tust.edu.cn.
- Publication Type:Journal Article
- Keywords:
AMP-activated protein kinase;
Diosmin;
Lipometabolism;
Metabolic dysfunction-associated steatotic liver disease;
Obesity
- MeSH:
Diosmin/administration & dosage*;
Animals;
AMP-Activated Protein Kinases/genetics*;
Humans;
Non-alcoholic Fatty Liver Disease/enzymology*;
Mice;
Obesity/enzymology*;
Hep G2 Cells;
Male;
3T3-L1 Cells;
Mice, Inbred C57BL;
Signal Transduction/drug effects*;
Lipid Metabolism/drug effects*;
Chrysanthemum/chemistry*;
Lipogenesis/drug effects*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2025;23(7):863-870
- CountryChina
- Language:English
-
Abstract:
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are linked to numerous chronic conditions, including cardiovascular disease, atherosclerosis, chronic kidney disease, and type II diabetes. Previous research identified the natural flavonoid diosmin, derived from Chrysanthemum morifolium, as a regulator of glucose metabolism. However, its effects on lipid metabolism and underlying mechanisms remained unexplored. The AMP-activated protein kinase (AMPK) pathway serves a critical function in glucose and lipid metabolism. The relationship between diosmin and the AMPK pathway has not been previously documented. This investigation examined diosmin's capacity to reduce lipid content through AMPK pathway activation in hepatoblastoma cell line G2 (HepG2) and 3T3-L1 cells. The study revealed that diosmin inhibits lipogenesis, indicating its potential as an anti-obesity agent in obese mice. Moreover, diosmin demonstrated effective MASLD alleviation in vivo. These findings suggest that diosmin may represent a promising therapeutic candidate for treating obesity and MASLD.
